FX.co ★ Halozyme: Takeda Receives Regulatory Approval For HYQVIA In Japan - Quick Facts

Halozyme Therapeutics (HALO) has announced that the Japanese Ministry of Health, Labour and Welfare has granted regulatory approval to Takeda for HYQVIA, intended for patients diagnosed with agammaglobulinemia or hypogammaglobulinemia. HYQVIA is notable for being the inaugural plasma-derived treatment in Japan designed for subcutaneous injection, combining one vial of Immunoglobulin 10% with one vial of Recombinant Human Hyaluronidase PH20, the latter of which utilizes Halozyme's proprietary ENHANZE drug delivery technology.

"We are thrilled that patients in Japan suffering from agammaglobulinemia or hypogammaglobulinemia now have the opportunity to benefit from HYQVIA. This therapy is distinct for being the only subcutaneous immunoglobulin treatment available that aims to minimize the frequency of dosing," remarked Helen Torley, CEO of Halozyme.